Ascendis Pharma Presents 3-Year Data At ASBMR 2024 Showing Long-Term Treatment With TransCon PTH Normalizes Bone Remodeling In Adults With Hypoparathyroidism
Ascendis Pharma Presents 3-Year Data At ASBMR 2024 Showing Long-Term Treatment With TransCon PTH Normalizes Bone Remodeling In Adults With Hypoparathyroidism
Ascendis Pharma在ASBMR 2024展示了爲期3年的數據，表明TransCon PTH的長期治療使甲狀旁腺功能減退成人的骨重塑恢復正常
Ascendis Pharma Presents 3-Year Data At ASBMR 2024 Showing Long-Term Treatment With TransCon PTH Normalizes Bone Remodeling In Adults With Hypoparathyroidism
Ascendis Pharma在ASBMR 2024展示了爲期3年的數據，表明TransCon PTH的長期治療使甲狀旁腺功能減退成人的骨重塑恢復正常
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間